T he 5 Neonatal Oxygen Prospective Meta-analysis (NeOProM) trials evaluated the effects, in infants born extremely preterm, of targeting lower (85%-89%) vs higher (91%-95%) pulse oximeter saturation (SpO2) on death or disability.
1 A meta-analysis shows that for every 1000 infants, targeting lower vs higher SpO2 led to no difference in the primary composite outcome of death or major disability up to 18-24 months and no difference in major disability, including blindness, but resulted in 28 more deaths, 22 more infants with necrotizing enterocolitis, but 42 fewer infants receiving treatment for retinopathy of prematurity. 2 A challenge in analyzing the trials was the discovery in 2011 of an artifact in the study oximeters' calibration. 3 Downloaded SpO2 values from Masimo oximeters in 176 infants born preterm in 35 neonatal units had a nonphysiological distribution with a large dip between 87% and 90% (Figure 1 ; available at www.jpeds.com). Masimo reported that this reflected their decision to adjust the calibration of their oximeters so that at values >87% the displayed SpO2 were increased by 1%-2%. 3 As well as fewer values than expected between 87% and 90%, this manufacturer-generated artifact returned more SpO2 values than expected >90%, 3 thus affecting both target groups in the NeOProM trials. By elevating SpO2 readings of 88% and 89% to greater displayed values, the artifact would be expected to make the low target group range of 85%-89% narrower and harder to target. By elevating SpO2 values in the range 90%-95% by 1%-2% above the true value the artifact would mean that actual achieved SpO2 values in the hightarget range with the original oximeters were lower than intended, narrowing the difference in SpO2 between groups.
Although the original oximeters performed within required standards for accuracy, at the investigators' request, Masimo provided revised software restoring the expected SpO2 distribution 3, 4 and the oximeters were changed to the revised software in 3 of the NeOProM trials. 4, 5 According to Masimo, oximeters sold since then have incorporated revised software.
The effect of the oximeter revision on targeting accuracy and mortality is debated. In an interim safety analysis of the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and UK trials, 6 the relative risk of 36-week mortality was increased by 65% in low-target vs high-target infants treated using revised oximeters (21.8% vs 13.3%; P < .001) but was not significantly different in low-target vs high-target infants treated using original oximeters (test for interaction between results for revised and original oximeters P = .006). Each trial was stopped early to prevent avoidable deaths that might occur with continuing enrollment. 6 Whyte et al found no difference in targeting accuracy between original and revised oximeters in the BOOST-II trials, 4, 7, 8 as measured by the difference in the median of the median SpO2 distributions for the low-and high-target groups. 9 They concluded that decisions about optimal SpO2 targets should not be restricted to data obtained with revised oximeters. 9 However, an infant's median SpO2 value does not describe the time they spent in their intended SpO2 target range, which is a more meaningful measure of targeting accuracy. We now report an infant-specific analysis of time spent in the intended SpO2 target ranges among infants managed using original and revised oximeters in the BOOST-II Australia and BOOST-II UK trials.
Methods
For each of the 2096 infants in the BOOST II Australia and UK trials for whom oxygen saturation data were available, we calculated the percentage of all time on the oximeter that the
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Pulse oximeter saturation infant spent at each SpO2 value. We then determined the proportion of time that each infant spent in the low-and hightarget ranges. Using these infant-specific proportions, within each randomized treatment group we calculated the difference between the original and revised oximeters in the mean proportion of time spent in each range, stratified by trial. For the low-target range, the net improvement in targeting was defined as the increase in the mean proportion of time spent in that range by infants in the low-target group minus any increase in the time spent in that range by infants in the hightarget group. Similarly, the net improvement in targeting of the high-target range was defined as the difference between the increase in time for infants allocated to the high-target group and the increase for infants in the low-target group. The overall improvement in targeting was then defined as the sum of these 2 improvements.
Because the infant-specific proportions of time spent in each range must lie between 0% and 100%, and because the times in the low-and high-target ranges for a particular infant are not independent, the assumptions required by standard parametric statistical methods do not hold. Therefore, we used nonparametric methods to draw inferences from these data.
To estimate nonparametric 95% CIs for the values of interest, we used bootstrapping 10 -randomly sampling infants from the original data with replacement mimics the process of sampling from the population-and we repeated this 10 000 times. By calculating the targeting improvements in each of these 10 000 resampled datasets, we obtained a distribution of "bootstrapped" parameter estimates, from which we obtained a plausible range for the true parameter of interest.
Nonparametric 2-sided P values were calculated by conducting permutation tests. 11, 12 This approach is based on the fact that we can produce a dataset in which we know the null hypothesis of no software effect is true by randomly shuffling the software labels between infants from the original dataset. We did this 10 000 times, allowing us to estimate the distribution of targeting improvements that could be observed if the null hypothesis were true. The P value is then the proportion of times that the magnitude of the targeting improvements calculated from the permuted datasets exceeded that observed in the original data.
Results
SpO2 data were available for 1128 of 1135 infants in BOOST-II Australia and for 968 of 973 infants in BOOST-II UK. Lowtarget group infants in BOOST-II Australia treated using revised oximeters spent 5.8% more time in the low SpO2 range of 85%-89% than those using the original oximeters. Similarly, in BOOST-II UK low-target infants treated using revised oximeters spent 5.3% more time in the low SpO2 range of 85%-89% than those using the original oximeters. High-target infants treated with revised oximeters spent 3.3% and 1.7% longer in the low SpO2 range than high-target infants treated with the original oximeters in the Australia and UK studies, respectively, leading to a pooled net improvement of 2.9% (95% CI 1.4%-4.4%; P < .001) in targeting the low range using revised oximeters across the 2 trials (Table I and Figure 2) .
In BOOST-II Australia, high-target infants treated using revised oximeters spent 3.2% more time in the high SpO2 range of 91%-95% than those treated using original oximeters, and low-target infants spent 0.1% longer in the high SpO2 range, giving a net improvement in targeting the high SpO2 range of 3.1%. In BOOST II UK, high-target infants treated using revised oximeters spent 4.5% less time in the high range than those using original oximeters, and low-target infants spent 2.2% less time in that range, giving a net deterioration in targeting accuracy of 2.2%. Pooling the data stratified by trial gave a net improvement in targeting the high-target range of 1.0% (95% CI 1.0% deterioration to 3.0% improvement; P = .322).
The combined net improvement of proportion of time spent in correct target range across both low-and high-target ranges associated with revised oximeters was 3.9% (95% CI 1.6%-6.2%; P < .001). Further results from the individual trials are provided in Tables II and III (available at www.jpeds.com). In relative terms, using revised vs original oximeters, low-target infants spent 30%-40% more time in the low-target range in the 2 trials.
Discussion
We have shown that the revision of the oximeter calibration software in the BOOST-II Australia and BOOST-II UK trials improved SpO2 targeting. This was mainly because the lowtarget infants on revised oximeters spent longer in their intended SpO2 range, increasing their exposure to lower SpO2. This may, at least in part, explain the increased differences in mortality observed between randomized groups using revised oximeters 2 and suggests that our current assessments of average treatment effects may underestimate the risk of targeting the lower SpO2 range.
In pooled analyses of the BOOST-II Australia and BOOST-II UK trials, there was not a statistically significant difference in mortality at 2 years between randomization groups with the original oximeters (P = .49), 13 but there was a highly statistically significant difference in mortality between groups with the revised oximeters (P = .001). The pooled mortality rate of the high-target groups decreased by 1.8% after the oximeter revision. The pooled mortality rate of the low-target groups increased by 7.5% after the oximeter revision. The changes in mortality observed following the oximeter revision were therefore largely explained by changes in mortality rates in the lowtarget groups.
The small net improvement in the pooled results in targeting the high SpO2 target range after the oximeter changes was not statistically significant. It is important to consider that displayed values in the higher target range after the oximeter revision represent higher true SpO2 readings than similar readings obtained with the original oximeters. The different patterns between the 2 trials in the high-target groups after the revision may be explained by chance.
As previously suggested, 9 our statistical method used "infant" as the unit of analysis by combining the data for each infant into a summary statistic followed by a comparison between target groups based on the between-infant variation in the summary statistic. Our use of percent time in the target range provides a more relevant metric of targeting accuracy than the median oxygen saturation for each infant previously presented. 9 It will be helpful if similar analyses are undertaken on the data from the other oxygen trials. 
CLINICAL AND LABORATORY OBSERVATIONS
We analyzed all time on the oximeter rather than time when breathing supplemental oxygen because the trials reported increased mortality with the lower SpO2 target range. Lower SpO2 values would be associated with relative hypoxemia whether or not supplemental oxygen was in use and would not result in oxygen supplementation in infants in the low SpO2 target groups.
In each trial using revised oximeters (BOOST-II UK, 4, 7, 13 BOOST-II Australia, 4, 7, 13 and the Canadian Oxygen Trial 5 ), the observed risk of death was greater in low-target infants, and the pooled mortality rate was statistically significantly greater in low-target infants. A test for interaction showed strong evidence (P = .009) that the pooled mortality results were different before and after the oximeter change (Figure 3 ; available at www.jpeds.com). The effect of additional centers joining the BOOST-II UK study is unlikely to explain this difference, as no new centers joined the Australian or Canadian trials after the oximeter revision. However, nurses in the 3 trials may have become better at SpO2 targeting over time, 2, 9 tending to increase the risk of mortality in lower-target infants. If so, this would strengthen the conclusion that spending more time in the lower saturation target increases mortality.
The NeOProM trials show collectively, and particularly in the infants who were treated after the revision of the trial oximeters, that small differences in achieved SpO2 distribution can have a significant effect on risk of mortality in infants born extremely preterm. Clinicians should understand the performance of the oximeters that they use and this would be facilitated if the manufacturers of these devices published details of the calibration of their instruments.
In summary, changing the trial oximeters improved targeting, exposing low-target infants to more time with lower SpO2 (P < .001), which was associated with an increased risk of mortality. The improved targeting was captured by measuring time spent in the intended SpO2 target ranges but not by measuring the difference in median SpO2. 9 Regardless of any effects of changing the oximeters on trial outcomes, the NeOProM trials show that aiming for the lower SpO2 target has no significant effect on the risk of the composite of death or disability, on disability or on blindness but increases the risk of death.
2 Any proposed trade-off 2 between the benefits (less treatment for retinopathy of prematurity, without differences in blindness or disability) and harms (more deaths and more necrotizing enterocolitis) of the low target should be made clear to parents. This information already is changing clinical practice. 
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